Myriad Genetics Inc (NASDAQ:MYGN)
| 19.24 Delayed Data As of Dec 01 |  +0.15 / +0.79%Today’s Change | 13.82 Today|||52-Week Range 24.21 | +32.60% Year-to-Date |
Latest MYGN News | Press Releases
| What's Driving Twist Bioscience Corp's Surprising 14% Stock Rally? Nov 29 / GuruFocus News - Paid Partner Content | Myriad Genetics (MYGN) Expands Pharma Services With New Pact Nov 20 / Zacks.com - Paid Partner Content |
| Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now Nov 21 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 19.09 |
| Today’s open | 18.72 |
| Day’s range | 18.66 - 19.27 |
| Volume | 16,294 |
| Average volume (3 months) | 589,986 |
| Market cap | $1.7B |
Data as of 3:59pm ET, 12/01/2023
Growth & Valuation
| Earnings growth (last year) | -298.51% |
| Earnings growth (this year) | -7.78% |
| Earnings growth (next 5 years) | -68.57% |
| Revenue growth (last year) | -1.77% |
| P/E ratio | NM |
| Price/Sales | 1.72 |
| Price/Book | 1.76 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CLDXCelldex Therapeutics... | +1.83 | +6.06% |
| ---- | ||
| ---- | ||
| VCYTVeracyte Inc | +0.93 | +3.63% |
Data as of 3:59pm ET, 12/01/2023
Financials
| Next reporting date | February 28, 2024 |
| EPS forecast (this quarter) | $0.04 |
| Annual revenue (last year) | $678.4M |
| Annual profit (last year) | -$112.0M |
| Net profit margin | -16.51% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
